

产品名称: (-)-Blebbistatin
 产品别名: (S)-(-)-Blebbistatin

生物活性:																														
Description	(-)-Blebbistatin is an S enantiomer of blebbistatin. Blebbistatin is a potent and selective myosin II inhibitor with IC ₅₀ s ranging from 0.5 to 5 μM.																													
IC₅₀ & Target	IC50: 0.5 to 5 μM (myosin II)[1]																													
In Vitro	Blebbistatin potently inhibits several striated muscle myosins as well as vertebrate nonmuscle myosin IIA and IIB with IC50 values ranging from 0.5 to 5 μM. Smooth muscle myosin is only poorly inhibited (IC50=80 μM)[1]. Blebbistatin does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. It blocks the myosin heads in a products complex with low actin affinity[2]. In culture-activated hepatic stellate cells, blebbistatin is found to change both cell morphology and function. Stellate cells become smaller, acquire a dendritic morphology and have less myosin IIA-containing stress fibres and vinculin-containing focal adhesions. Blebbistatin impairs silicone wrinkle formation, reduces collagen gel contraction and blocks endothelin-1-induced intracellular Ca ²⁺ release. It promotes wound-induced cell migration[3].																													
In Vivo	Blebbistatin dose-dependently and completely relax both KCl- and carbachol-induced rat detrusor and endothelin-1-induced human bladder contraction. Pre-incubation with 10 μM blebbistatin attenuates carbachol responsiveness by 65% while blocking electrical field stimulation-induced bladder contraction reaching 50% inhibition at 32 Hz[4].																													
Solvent&Solubility	In Vitro: DMSO : 5.2 mg/mL (17.79 mM; Need ultrasonic and warming) H₂O : < 0.1 mg/mL (insoluble)																													
		<table border="1"> <thead> <tr> <th>Solvent</th> <th>Mass</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>Concentration</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>1 mM</td> <td></td> <td>3.4208 mL</td> <td>17.1040 mL</td> <td>34.2079 mL</td> </tr> <tr> <td>5 mM</td> <td></td> <td>0.6842 mL</td> <td>3.4208 mL</td> <td>6.8416 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.3421 mL</td> <td>1.7104 mL</td> <td>3.4208 mL</td> </tr> </tbody> </table>	Solvent	Mass	1 mg	5 mg	10 mg	Concentration					1 mM		3.4208 mL	17.1040 mL	34.2079 mL	5 mM		0.6842 mL	3.4208 mL	6.8416 mL	10 mM		0.3421 mL	1.7104 mL	3.4208 mL			
	Solvent	Mass	1 mg	5 mg	10 mg																									
	Concentration																													
	1 mM		3.4208 mL	17.1040 mL	34.2079 mL																									
5 mM		0.6842 mL	3.4208 mL	6.8416 mL																										
10 mM		0.3421 mL	1.7104 mL	3.4208 mL																										
Preparing	1 mM	3.4208 mL	17.1040 mL	34.2079 mL																										
Stock Solutions	5 mM	0.6842 mL	3.4208 mL	6.8416 mL																										
	10 mM	0.3421 mL	1.7104 mL	3.4208 mL																										
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存：体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 1 mg/mL (3.42 mM); Clear solution</p> <p>此方案可获得 ≥ 1 mg/mL (3.42 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀，向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p>																														

	<p>2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: 1 mg/mL (3.42 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 1 mg/mL (3.42 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: ≥ 1 mg/mL (3.42 mM); Clear solution</p> <p>此方案可获得 ≥ 1 mg/mL (3.42 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
<p>References</p>	<p>[1]. Limouze J, et al. Specificity of blebbistatin, an inhibitor of myosin II. J Muscle Res Cell Motil. 2004;25(4-5):337-41.</p> <p>[2]. Kovács M, et al. Mechanism of blebbistatin inhibition of myosin II. J Biol Chem. 2004 Aug 20;279(34):35557-63.</p> <p>[3]. Liu Z, et al. Blebbistatin inhibits contraction and accelerates migration in mouse hepatic stellate cells. Br J Pharmacol. 2010 Jan 1;159(2):304-15.</p> <p>[4]. Zhang X, et al. In vitro and in vivo relaxation of urinary bladder smooth muscle by the selective myosin IIinhibitor, blebbistatin. BJU Int. 2011 Jan;107(2):310-7.</p>
<p>实验参考：</p>	
<p>Cell Assay</p>	<p>Freshly isolated HSCs are replated on 96-well plate. At day 3, medium is replaced by serum-free medium and cells are starved overnight, treated with or without blebbistatin (25 μM) for 2 h followed by stimulation with platelet-derived growth factor-BB (20 ng/mL). After an overnight incubation, the WST-1 cell proliferation assay are performed[3].</p>
<p>References</p>	<p>[1]. Limouze J, et al. Specificity of blebbistatin, an inhibitor of myosin II. J Muscle Res Cell Motil. 2004;25(4-5):337-41.</p> <p>[2]. Kovács M, et al. Mechanism of blebbistatin inhibition of myosin II. J Biol Chem. 2004 Aug 20;279(34):35557-63.</p> <p>[3]. Liu Z, et al. Blebbistatin inhibits contraction and accelerates migration in mouse hepatic stellate cells. Br J Pharmacol. 2010 Jan 1;159(2):304-15.</p> <p>[4]. Zhang X, et al. In vitro and in vivo relaxation of urinary bladder smooth muscle by the selective myosin IIinhibitor, blebbistatin. BJU Int. 2011 Jan;107(2):310-7.</p>